About this item:

448 Views | 872 Downloads

Author Notes:

Correspondence: minkchawla@gmail.com

All authors helped to write, edit, and craft the manuscript, and all authors have read and approved the final version of the manuscript.

Competing interests: LSC is currently on sabbatical as an employee and stock holder of La Jolla Pharmaceutical Company (LJPC), which is the sponsor of the ATHOS 3 Trial. LWB is a site investigator in the ATHOS 3 trial and reports receiving consulting fees from LJPC. EBM and ZA declare that they have no competing interests.

Subjects:

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Critical Care Medicine
  • General & Internal Medicine
  • CONVERTING ENZYME-ACTIVITY
  • SEPTIC SHOCK
  • NOREPINEPHRINE
  • VASOPRESSIN
  • MANAGEMENT

The use of angiotensin II in distributive shock

Tools:

Journal Title:

Critical Care

Volume:

Volume 20, Number 1

Publisher:

, Pages 137-137

Type of Work:

Article | Final Publisher PDF

Copyright information:

© 2016 Chawla et al.

Export to EndNote